聚乙二醇干扰素α-2a联合利巴韦林标准抗病毒治疗慢性丙型肝炎患者疗效再研究*

doi:10.3969/j.issn.1672-5069.2022.04.012

Abstract

Abstract: Objective The aim of this study was to investigate the efficacy of standardized pegylated interferon α-2a (Peg-IFNα-2a) and ribavirin (RBV) combination in treatment of patients with chronic hepatitis C (CHC). Methods 102 patients with CHC were enrolled in our hospital between February 2017 and April 2020, and were divided randomly into control (n=50) and observation (n=52). The patients in the control received RBV and interferonα-2a therapy, and those in the observation were treated by RBV and Peg-IFNα-2a therapy. The regimen in both groups lasted for 6 months. The peripheral blood T lymphocyte subsets was detected by Flow cytometry. Results The end treatment virological response (ETVR) and the sustained virological response in the observation group were 88.5% and 82.7%, both significantly higher than 62.0% and 62.0%(P＜0.05) in the control group; at the end of treatment, serum ALT and AST levels in the observation were (36.8±4.1)U/L and (38.4±3.4)U/L, both significantly lower than [(61.5±4.3)U/L and(51.6±3.6)U/L, respectively, P＜0.05] in the control group; at week 4, 12 and 24, serum HCV RNA loads in the observation group were (4.6±1.2)Ig IU/mL, (4.1±1.1)Ig IU/mL and (3.6±0.9)Ig IU/mL, all significantly lower than [(5.1±1.1)Ig IU/mL, (4.7±1.2)Ig IU/mL and (4.2±1.0)Ig IU/mL, respectively, P＜0.05] in the control; at the end of the regimen, the percentage of peripheral blood CD3⁺ cells in the observation group was (73.8±7.5)%, significantly higher than [(65.6±6.9)%, P＜0.05], that of CD4⁺ cells was (49.5±6.3)%, significantly higher than [(34.8±5.8)%, P＜0.05], while that of CD8⁺ cells was (17.6±3.8)%, significantly lower than [(25.9±4.6)%, P＜0.05] and the ratio of CD4⁺/CD8⁺ cells was (1.0±0.2), significantly lower than [(1.4±0.3), P＜0.05] in the control group. Conclusion The standardized Peg-IFNα-2a and RBV antiviral therapy is still efficacious in treating patients with CHC, which might be carried out alternatively in case no direct antiviral agents is available.

Key words: Hepatitis C, Pegylated interferon α, Ribavirin, Therapy

Xu Huan, Wang Guangli, Dong Dandan, et al. Efficacy of standardized pegylated interferon α-2a and ribavirin combination in treatment of patients with chronic hepatitis C[J]. Journal of Practical Hepatology, 2022, 25(4): 500-503.

References

[1] Hallager S, Ladelund S, Kjaer M, et al. Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: A nationwide cohort study. J Viral Hepat, 2018, 25(1):47-55.
[2] Sofia D, Dinis MM, Arlindo CR, et al. Successful treatment of chronic hepatitis C in a kidney transplant patient with only 2 weeks of direct-acting antiviral therapy. Nefrología, 2018,38(6):671-672.
[3] 张艳芳,李用国,兰英华. 比较西甲匹韦与特拉匹韦联合聚乙二醇干扰素及利巴韦林的三联方案治疗慢性丙型肝炎基因1型患者的meta分析. 中华传染病杂志,2018,36(8):473-479.
[4] Omar H, Akel WE, Elbaz T, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther, 2018,47(3):421-431.
[5] Ferreira VL, Tonin FS, Jarek NA, et al. Efficacy ofinterferon-free therapies for chronic hepatitis C: A systematic review of all randomized clinical trials. Clin Drug Invest, 2017, 37(7):1-12.
[6] 段军民,李素森,刘丽珍,等. 聚乙二醇干扰素α-2a与普通干扰素α-2b联合利巴韦林治疗慢性丙型肝炎患者疗效比较和影响疗效的预测因素分析. 实用肝脏病杂志,2018,21(1):64-67.
[7] 中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2019年版). 中华传染病杂志,2020,38(1):9-28.
[8] 中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2015年更新版). 中华实验和临床感染病杂志(电子版),2015,9(5):590-607.
[9] SchìtzA, Moser S, Marchart K, et al. Direct observed therapy of chronic hepatitis C with an interferon-free all-oral regimen at a low-threshold drug treatment facility-a new concept for treatment of patients with borderline compliance receiving opioid substitution therapy. Am J Gastroenterol, 2016, 111(6):903-905.
[10] Saab S, Jimenez M, Fong T, et al. Accessibility tooral antiviral therapy for patients with chronic hepatitis C in the United States. J Clin Transl Hepatol, 2016, 4(2):76-82.
[11] Sáez-RoyuelaF, Badia E . Sofosbuvir plus ribavirin in Asian patients with chronic genotype 2 hepatitis C virus infection: history of a success? Liver Int, 2016, 36(8):1093-1095.
[12] Anderson FH, Zeng L, Yoshida EM, et al. Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C. Can J Gastroenterol, 2016, 11(4):294-297.
[13] Masarova L, Yin CC, Cortes JE, et al. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol, 2017, 6(1):30.
[14] Ide K, Sato I, Imai T, et al. Comparison of the safety profiles of pegylated interferon α-2a and α-2b administered in combination with ribavirin for chronic hepatitis C infection: A real-world retrospective cohort study. Biol Pharm Bull, 2016,39(12):2060-2065.
[15] Shinoda M, Ebinuma H, Itano O, et al. Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res, 2016,46(11):1118-1128.
[16] Abdel-Hamid NM, Wahid A, Nazmy MH, et al. Synergisticeffects of Jerusalem artichoke in combination with pegylated interferon alfa-2a and ribavirin against Hepatic fibrosis in rats. Asian Pac J Cancer Prev, 2016, 17(4):1979-1985.
[17] Masarova L, Patel KP, Newberry KJ, et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol, 2017, 4(4):e165-e175.
[18] Sugimoto R, Iwasa M, Hara N, et al. Changes in liver function and body composition by direct-acting antiviral therapy for hepatitis C virus infection. Hepatol Res, 2017,48(5):337-344.
[19] Kong FY, Feng B, Zhang HH, et al. CD4⁺CXCR5⁺ T cells activate CD27⁺IgG⁺ B cells via IL-21 in patients with hepatitis C virus infection. Hepatobiliary Pancreat Dis Int, 2016, 15(1):55-64.
[20] Tan MP, Dolton GM, Geddy AB, et al. Human leucocyte antigen class I-redirected anti-tumour CD4⁺T cells require a higher T cell receptor binding affinity for optimal activity than CD8⁺T cells. Clin Exp Immunol, 2017, 187(1):124-137.
[21] Megahed A, Salem N, Fathy A, et al. Pegylated interferon α/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection. World J Pediatr, 2017, 13(4):346-352.
[22] Manuela P, Gaetano B, Caterina G, et al. Resveratrol inhepatitis C patients treated with pegylated-interferon-α-2b and ribavirin reduces sleep disturbance. Nutrients, 2017, 9(8):897.
[23] Gayam V, Khalid M, Mandal AK, et al.Direct-acting antivirals in chronic hepatitis C genotype 4 infection in community care setting. Gastroenterol Res, 2018, 11(2):130-137.

Efficacy of standardized pegylated interferon α-2a and ribavirin combination in treatment of patients with chronic hepatitis C

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liu Lin, Hu Yun, Xu Lan. Lifestyle management of individuals with glucose and lipid metabolism disorders- related diseases [J]. Journal of Practical Hepatology, 2022, 25(4): 464-467.
[2]	Jia Ting, Li Junyi, Zhang Xiuling, et al. Serologic response toentecavir and pegylated interferon α-2b combination in treatment of patients with low serum level HBsAg-positive chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(4): 488-491.
[3]	Liu Yuying, Zhang Jiaozhen, Zhou Haijuan, et al. Response to tenofovir antiviral therapy different in patients with chronic hepatitis B and different HBV genotype infection? [J]. Journal of Practical Hepatology, 2022, 25(4): 492-495.
[4]	Luo Zhenzhen, Tian Haiying, Ge Jianhua, et al. Clinical evaluation of liver fibrosis by serum N-oligosaccharide and bile acid levels and liver stiffness measurement combination in patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2022, 25(4): 504-507.
[5]	Li Yawen, Zhou Jun. Clinical efficacy of Huatan Qushi Shugan decoction and simvastatin combination in the treatment of patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2022, 25(4): 526-529.
[6]	Ji Xuechun, Jin Shizhu, Nipal Narayan, et al. Endoscopic management of superior esophageal variceal bleeding: a 10-year single center retrospective experience [J]. Journal of Practical Hepatology, 2022, 25(4): 530-533.
[7]	Liu Hao, Zhou Feifei, Sun Haokai, et al. CBCT-based 3D reconstruction technique in the identification of blood supplying arteries during TACE operation for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(4): 563-566.
[8]	Wang Yuanping, Zheng Lulu, Zhang Guangliang. A pilot study of MR and 4DCT images in the delineation of target area in patients with primary liver cancer undergoing first radiotherapy [J]. Journal of Practical Hepatology, 2022, 25(4): 567-570.
[9]	Zhang Jing, Lin Ting, Sun Xiang. Percutaneous cather drainage under ultrasound guidance with lauromacrogol replacement for sclerotherapy in patients with huge hepatic cysts [J]. Journal of Practical Hepatology, 2022, 25(4): 571-574.
[10]	Lin Yikun, Xie Lang, Fu Jianming, et al. Clinical efficacy of partial hepatectomy and choledochojejunostomy combination in the treatment of patients with hepatolithiasis and risk factors for postoperative recurrence [J]. Journal of Practical Hepatology, 2022, 25(4): 591-594.
[11]	Huang Peng, Meng Fanbin, Zhang Xiao, et al. Efficacy of percutaneous transhepatic puncture choledochoscopic lithotomy under CT 3D guidance in the treatment of patients with complex hepatolithiasis [J]. Journal of Practical Hepatology, 2022, 25(4): 595-598.
[12]	Zou Ji, Chen Xiaobo, Dong Renhua, et al. Long-term survival of patients with stageT1b gallbladder cancer after cholecystectomy and wedge resection of liver tissues and regional lymph node dissection combination therapy [J]. Journal of Practical Hepatology, 2022, 25(4): 599-602.
[13]	Wei Bowen, Ren Zheng, Zhang Liang, et al. Enhanced CT scanning in evaluating residual tumor in patients with primary liver cancer after TACE theapy [J]. Journal of Practical Hepatology, 2022, 25(4): 603-604.
[14]	Huang Junrong, Wu Changru, Wu Jianlin. Short-term observation of entecavir and magnesium isoglycyrrhizinate in treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(3): 327-330.
[15]	Zou Donghua, Mi Jianwei, Li Yuling, et al. Rescued therapy of patients with chronic hepatitis B and rtA181V/T mutation by adefovir dipivoxiland entecavir or tenofovir combination [J]. Journal of Practical Hepatology, 2022, 25(3): 331-334.